1-6 of 6
Qi Xia
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes

Uwe Platzbecker, Valeria Santini, Amer M. Zeidan, Mikkael A. Sekeres, Pierre Fenaux, Azra Raza, Moshe Mittelman, Sylvain Thépot, Rena Buckstein, Ulrich Germing, Yazan F Madanat, Maria Diez-Campelo, David Valcarcel, Anna Jonasova, Souria Dougherty, Sheetal Shah, Qi Xia, Libo Sun, Shyamala Navada, Michael R. Savona, Rami S. Komrokji
Journal: Blood
Blood (2024) 144 (Supplement 1): 352.
https://doi.org/10.1182/blood-2024-203612
Published: 2024
Journal Articles

Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents

Rami S. Komrokji, Valeria Santini, Uwe Platzbecker, Koen Van Eygen, Maria Diez-Campelo, Raquel De Paz, Guillermo Sanz, Sylvain Thépot, Maciej Kaźmierczak, Esther Natalie Oliva, Mikkael A. Sekeres, Pierre Fenaux, Yazan F. Madanat, Michael R. Savona, Jennifer Riggs, Souria Dougherty, Ashley Lennox, Qi Xia, Libo Sun, Tymara Berry, Amer M. Zeidan
Journal: Blood
Blood (2024) 144 (Supplement 1): 4590.
https://doi.org/10.1182/blood-2024-200885
Published: 2024
Journal Articles

Improvement of Patient-Reported Outcomes Among Heavily Pretreated Patients with Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated with Imetelstat on the IMerge Phase 3 Trial

Mikkael A. Sekeres, Maria Diez-Campelo, Amer M. Zeidan, Uwe Platzbecker, Antoine Regnault, Kristin Creel, Nishan Sengupta, Ying Wan, Libo Sun, Qi Xia, Tymara Berry, Souria Dougherty, Sheetal Shah, Shyamala Navada, Valeria Santini, David Valcárcel
Journal: Blood
Blood (2023) 142 (Supplement 1): 6479.
https://doi.org/10.1182/blood-2023-181103
Published: 2023
Journal Articles

Durable Continuous Transfusion Independence (TI) with Imetelstat in IMerge Phase 3 for Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents (ESAs)

Uwe Platzbecker, Rami S. Komrokji, Amer M. Zeidan, Pierre Fenaux, Mikkael A. Sekeres, Michael R. Savona, Yazan F. Madanat, Anna Jonášová, Thomas Illmer, Laurie Sherman, Tymara Berry, Jennifer Riggs, Qi Xia, Shyamala Navada, Ying Wan, Fei Huang, Faye M. Feller, Valeria Santini
Journal: Blood
Blood (2023) 142 (Supplement 1): 4605.
https://doi.org/10.1182/blood-2023-181154
Published: 2023
Journal Articles

Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study

Rami S. Komrokji, Valeria Santini, Pierre Fenaux, Michael R. Savona, Yazan F. Madanat, Tymara Berry, Laurie Sherman, Shyamala Navada, Faye M. Feller, Libo Sun, Qi Xia, Ying Wan, Fei Huang, Amer M. Zeidan, Uwe Platzbecker
Journal: Blood
Blood (2023) 142 (Supplement 1): 194.
https://doi.org/10.1182/blood-2023-181237
Published: 2023
Journal Articles

Impact of Mutational Status on Clinical Response to Imetelstat in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Phase 3 Study

Valeria Santini, Amer M. Zeidan, Pierre Fenaux, Yazan F. Madanat, Tymara Berry, Faye M. Feller, Libo Sun, Qi Xia, Ying Wan, Fei Huang, Michael R. Savona, Uwe Platzbecker
Journal: Blood
Blood (2023) 142 (Supplement 1): 4603.
https://doi.org/10.1182/blood-2023-179378
Published: 2023